Arachidonyl ethanolamide (Anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus

T. Wenger, Khalid A. Jamali, Christian Juanéda, Jean Léonardelli, Gérard Tramu

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Arachidonyl ethanolamide, anandamide (ANA) was administered to male rats via a single i.p. injection at a dose of 0.02 mg/kg. In an parallel experiment ANA injection was preceded by the injection of SR 141716 (1.0 mg/kg), a selective and potent cannabinoid receptor antagonist. We observed using FOS protein immunocytochemistry that the parvocellular part of hypothalamic paraventricular nucleus (PVN) was activated as soon as 45 min. after ANA injection, i.e. the PVN showed an increased FOS immunoreactivity (FOSir). The peak level of FOSir was observed 90 min. after treatment. Meanwhile serum ACTH and corticosterone levels, as measured by radioimmunoassay, also significantly increased, 180 min. following drug injection both FOSir and serum hormone levels had returned to normal. SR 141716 did not antagonize these effects of ANA. We postulate that the locus of action of ANA the activation of the hypothalamo-pituitary-adrenal (HPA) axis is the parvocellular part of PVN. This activation may occur via a possible central cannabinoid receptor for which SR 141716 is not an effective antagonist. The rapid central response and activation of the HPA axis further support the view that ANA may be a central neurotransmitter or neuromodulator.

Original languageEnglish
Pages (from-to)724-728
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume237
Issue number3
DOIs
Publication statusPublished - Aug 28 1997

Fingerprint

rimonabant
Paraventricular Hypothalamic Nucleus
Injections
Chemical activation
Neurotransmitter Agents
Cannabinoid Receptor Antagonists
Cannabinoid Receptors
Corticosterone
Serum
Adrenocorticotropic Hormone
Radioimmunoassay
anandamide
Rats
Immunohistochemistry
Hormones
Pharmaceutical Preparations
Proteins
Experiments

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Arachidonyl ethanolamide (Anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. / Wenger, T.; Jamali, Khalid A.; Juanéda, Christian; Léonardelli, Jean; Tramu, Gérard.

In: Biochemical and Biophysical Research Communications, Vol. 237, No. 3, 28.08.1997, p. 724-728.

Research output: Contribution to journalArticle

Wenger, T. ; Jamali, Khalid A. ; Juanéda, Christian ; Léonardelli, Jean ; Tramu, Gérard. / Arachidonyl ethanolamide (Anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus. In: Biochemical and Biophysical Research Communications. 1997 ; Vol. 237, No. 3. pp. 724-728.
@article{ba13a1926bb44606b16de29829250584,
title = "Arachidonyl ethanolamide (Anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus",
abstract = "Arachidonyl ethanolamide, anandamide (ANA) was administered to male rats via a single i.p. injection at a dose of 0.02 mg/kg. In an parallel experiment ANA injection was preceded by the injection of SR 141716 (1.0 mg/kg), a selective and potent cannabinoid receptor antagonist. We observed using FOS protein immunocytochemistry that the parvocellular part of hypothalamic paraventricular nucleus (PVN) was activated as soon as 45 min. after ANA injection, i.e. the PVN showed an increased FOS immunoreactivity (FOSir). The peak level of FOSir was observed 90 min. after treatment. Meanwhile serum ACTH and corticosterone levels, as measured by radioimmunoassay, also significantly increased, 180 min. following drug injection both FOSir and serum hormone levels had returned to normal. SR 141716 did not antagonize these effects of ANA. We postulate that the locus of action of ANA the activation of the hypothalamo-pituitary-adrenal (HPA) axis is the parvocellular part of PVN. This activation may occur via a possible central cannabinoid receptor for which SR 141716 is not an effective antagonist. The rapid central response and activation of the HPA axis further support the view that ANA may be a central neurotransmitter or neuromodulator.",
author = "T. Wenger and Jamali, {Khalid A.} and Christian Juan{\'e}da and Jean L{\'e}onardelli and G{\'e}rard Tramu",
year = "1997",
month = "8",
day = "28",
doi = "10.1006/bbrc.1997.7222",
language = "English",
volume = "237",
pages = "724--728",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Arachidonyl ethanolamide (Anandamide) activates the parvocellular part of hypothalamic paraventricular nucleus

AU - Wenger, T.

AU - Jamali, Khalid A.

AU - Juanéda, Christian

AU - Léonardelli, Jean

AU - Tramu, Gérard

PY - 1997/8/28

Y1 - 1997/8/28

N2 - Arachidonyl ethanolamide, anandamide (ANA) was administered to male rats via a single i.p. injection at a dose of 0.02 mg/kg. In an parallel experiment ANA injection was preceded by the injection of SR 141716 (1.0 mg/kg), a selective and potent cannabinoid receptor antagonist. We observed using FOS protein immunocytochemistry that the parvocellular part of hypothalamic paraventricular nucleus (PVN) was activated as soon as 45 min. after ANA injection, i.e. the PVN showed an increased FOS immunoreactivity (FOSir). The peak level of FOSir was observed 90 min. after treatment. Meanwhile serum ACTH and corticosterone levels, as measured by radioimmunoassay, also significantly increased, 180 min. following drug injection both FOSir and serum hormone levels had returned to normal. SR 141716 did not antagonize these effects of ANA. We postulate that the locus of action of ANA the activation of the hypothalamo-pituitary-adrenal (HPA) axis is the parvocellular part of PVN. This activation may occur via a possible central cannabinoid receptor for which SR 141716 is not an effective antagonist. The rapid central response and activation of the HPA axis further support the view that ANA may be a central neurotransmitter or neuromodulator.

AB - Arachidonyl ethanolamide, anandamide (ANA) was administered to male rats via a single i.p. injection at a dose of 0.02 mg/kg. In an parallel experiment ANA injection was preceded by the injection of SR 141716 (1.0 mg/kg), a selective and potent cannabinoid receptor antagonist. We observed using FOS protein immunocytochemistry that the parvocellular part of hypothalamic paraventricular nucleus (PVN) was activated as soon as 45 min. after ANA injection, i.e. the PVN showed an increased FOS immunoreactivity (FOSir). The peak level of FOSir was observed 90 min. after treatment. Meanwhile serum ACTH and corticosterone levels, as measured by radioimmunoassay, also significantly increased, 180 min. following drug injection both FOSir and serum hormone levels had returned to normal. SR 141716 did not antagonize these effects of ANA. We postulate that the locus of action of ANA the activation of the hypothalamo-pituitary-adrenal (HPA) axis is the parvocellular part of PVN. This activation may occur via a possible central cannabinoid receptor for which SR 141716 is not an effective antagonist. The rapid central response and activation of the HPA axis further support the view that ANA may be a central neurotransmitter or neuromodulator.

UR - http://www.scopus.com/inward/record.url?scp=0031589566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031589566&partnerID=8YFLogxK

U2 - 10.1006/bbrc.1997.7222

DO - 10.1006/bbrc.1997.7222

M3 - Article

C2 - 9299434

AN - SCOPUS:0031589566

VL - 237

SP - 724

EP - 728

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -